Successful Use of Brigatinib Followed By Allogeneic Stem Cell Transplantation in Primary Refractory Anaplastic Lymphoma-Kinase Positive Large B Cell Lymphoma

Anaplastic lymphoma-kinase (ALK) positive large B cell lymphoma (LBCL) is a rare, aggressive lymphoma with high relapse rates and poor response to standard cytotoxic therapy. Brigatinib, a next-generation multi-kinase inhibitor that blocks signal transduction associated with the ALK mutational re-arrangement, has shown substantial efficacy in patients with ALK-positive non-small cell lung cancer. We present a unique and successful case of a...